title: Use of basiliximab in conjunction with either Neora/MMF/steroids or Prograf/MMF/steroids in simultaneous pancreas-kidney transplantation.
authors.affiliation: Centro Regionale di Riferimento per la Cura delle Malattie del Pancreas, Regione Toscana, Pisa, Italy.
authors.forename: U
authors.initials: U
authors.lastname: Boggi
authors.forename: F
authors.initials: F
authors.lastname: Vistoli
authors.forename: A
authors.initials: A
authors.lastname: Coppelli
authors.forename: P
authors.initials: P
authors.lastname: Marchetti
authors.forename: G
authors.initials: G
authors.lastname: Rizzo
authors.forename: F
authors.initials: F
authors.lastname: Mosca
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000077552:Basiliximab; D002423:Cause of Death; D016572:Cyclosporine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality; D011993:Recombinant Fusion Proteins; D012449:Safety; D013256:Steroids / Q000627:therapeutic use*; D016559:Tacrolimus / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007166:Immunosuppressive Agents; D011993:Recombinant Fusion Proteins; D013256:Steroids; D016572:Cyclosporine; D000077552:Basiliximab; D009173:Mycophenolic Acid; D016559:Tacrolimus